Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015', provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Complicated Skin And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Complicated Skin And Skin Structure Infections (cSSSI) Overview 7 Therapeutics Development 8 Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Overview 8 Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis 9 Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics under Development by Companies 10 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Complicated Skin And Skin Structure Infections (cSSSI) - Products under Development by Companies 14 Complicated Skin And Skin Structure Infections (cSSSI) - Companies Involved in Therapeutics Development 15 Cempra, Inc. 15 CrystalGenomics, Inc. 16 Debiopharm International S.A. 17 Dong-A Socio Group 18 GlaxoSmithKline plc 19 Melinta Therapeutics, Inc 20 Phosphagenics Limited 21 Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 30 CG-400549 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Debio-1450 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Debio-1452 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 delafloxacin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 fusidic acid - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 GSK-2140944 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 iclaprim mesylate - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 lanopepden - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecule for Skin Infections - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 tedizolid phosphate - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Complicated Skin And Skin Structure Infections (cSSSI) - Recent Pipeline Updates 51 Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects 67 Complicated Skin And Skin Structure Infections (cSSSI) - Product Development Milestones 68 Featured News & Press Releases 68 Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 68 Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 68 Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H1 2015 8 Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Cempra, Inc., H1 2015 15 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by CrystalGenomics, Inc., H1 2015 16 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Debiopharm International S.A., H1 2015 17 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Dong-A Socio Group, H1 2015 18 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by GlaxoSmithKline plc, H1 2015 19 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Melinta Therapeutics, Inc, H1 2015 20 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Phosphagenics Limited, H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 29 Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Recent Pipeline Updates, H1 2015 51 Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects, H1 2015 67
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
